

Discovery of drug candidate for HER2 positive Breast cancer treatment using HER2 targeted Small molecule with high brain permeability

B2SBio Inc.



ONCOLOGY	Candidate
Product Type	Chemical Product
Indication	1st indication: HER2 Positive Breast Cancer Metastatic HER2 Positive Breast Cancer including Brain Metastases 2nd indication: HER2 Positive Gastric Cancer
Target	Human Epidermal Growth Factor Receptor 2 (HER2)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Irreversible tyrosine kinase inhibitor forming a covalent bond with Cysteine 805 in HER2 • Binds to the ATP-binding pocket in HER2 • Inhibits the downstream signaling of HER2 and HER3 through the MAPK/ERK and PI3K/Akt pathways
Competitiveness	<ul style="list-style-type: none"> • Improved efficacy against HER2 positive breast cancer including brain metastases due to high brain exposure and activity • Expansion of indications to other HER2 positive solid cancers as well as HER2 positive breast cancer
Development Stage	Candidate
Route of Administration	Oral Administration